Previous Close | 23.98 |
Open | 24.08 |
Bid | 24.24 x 0 |
Ask | 24.46 x 0 |
Day's Range | 24.08 - 24.08 |
52 Week Range | 16.24 - 25.90 |
Volume | |
Avg. Volume | 2 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Jul 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024